Breast Cancer

Breast cancer is the most extensively studied tumour setting in the berberine literature.

That matters because the research is not limited to one subtype. Berberine has been studied across triple-negative, ER-positive, and HER2-positive models, with different mechanisms standing out in each.

Related treatment context

If the practical question is ER-positive, HER2-negative disease on abemaciclib or ribociclib, also see CDK4/6 Options and Supplement Considerations.

That page covers where berberine may sit around CDK4/6 therapy, and where the interaction burden becomes the bigger issue.

Why berberine stands out here

Breast cancer shows the widest subtype spread in the berberine evidence base.

The main themes are:

• apoptosis and cell-cycle arrest

• endocrine sensitisation

• radiosensitisation

• ferroptosis relevance

• EMT and metastasis suppression

• reversal of targeted-therapy resistance in selected HER2-positive models

Triple-negative breast cancer

TNBC is one of the strongest berberine settings because it lacks many of the targeted options available in other subtypes.

Reported findings include:

• growth inhibition across multiple TNBC cell lines

• subtype-dependent cell-cycle arrest

• activation of caspases and PARP cleavage

• radiosensitisation

• ferroptosis induction in selected models

• broad glycolysis suppression through the LH2 / PKM2 / LDHA network

• reversal of EMT-related behaviour

This gives TNBC one of the clearest multi-mechanism rationales for berberine.

ER-positive / luminal breast cancer

In ER-positive breast cancer, berberine has shown both direct activity and combination relevance.

The main findings include:

• G1 arrest in MCF-7 cells

• a shift in the BAX/BCL-2 balance toward apoptosis

• modulation of the miR-203 / Bcl-w axis

• sensitisation to tamoxifen, including resistant variants in preclinical models

That makes ER-positive disease one of the stronger settings for berberine as an endocrine-sensitising adjunct under investigation.

HER2-positive breast cancer

The key berberine finding here is lapatinib resistance reversal.

In resistant HER2-positive models, berberine increased ROS and weakened the tumour's antioxidant protection through Nrf2-related signalling changes.

That is one of the clearest examples in the literature of berberine helping dismantle a targeted-therapy resistance shield.

Broader breast-cancer themes

Across breast-cancer models, berberine has also shown:

• reduced metastatic signalling through MMP suppression and E-cadherin support

• reduced cancer stem-like behaviour

• multi-pathway effects that cross subtype boundaries

Practical interpretation

Breast cancer is berberine's most nuanced tumour-specific page.

The strongest current rationale differs by subtype:

• TNBC: ferroptosis, radiosensitisation, metabolic pressure, and anti-EMT activity

• ER-positive: tamoxifen sensitisation and apoptosis support

• HER2-positive: reversal of lapatinib resistance via ROS and Nrf2-linked mechanisms

This is still a preclinical evidence base.

Even so, breast cancer is one of the best-developed areas for understanding how berberine might be matched to tumour biology.

References

Breast Cancer — TNBC ⭐⭐⭐⭐

Multi-cell-line activity and subtype-specific mechanisms:

Mukherjee S, et al. (2020). Berberine Impairs the Survival of Triple Negative Breast Cancer Cells: A Comparison with Cisplatin and Illustration of Different Mechanistic Profiles. Nutrition and Cancer, 72(2):774–790.
🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC7036777/[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC7036777/)

Radiosensitisation via LIGIII/DNA repair:

(2025). Berberine Sensitises Breast Cancer Cells to Radiation via the Impairment of DNA Repair through LIGIII. International Journal of Molecular Sciences (PMC).
🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC12414796/[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414796/)

Breast Cancer — ER+ ⭐⭐⭐⭐

Tamoxifen sensitisation and comprehensive subtype review:

Ahmad F, et al. (2022). Berberine as a potential agent for breast cancer therapy. Frontiers in Pharmacology / PMC review.
🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC9480097/[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480097/)

Breast Cancer — HER2+ ⭐⭐⭐

Lapatinib resistance reversal via Nrf2/ROS:

(Covered within the broader Nrf2 inhibitors in cancer therapy review)
Robledinos-Antón N, et al. (2019). Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative Medicine and Cellular Longevity.
🔗 https://onlinelibrary.wiley.com/doi/10.1155/2019/9372182